There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October.

As COVID market narrows, SaNOtize moves to carve a new one: over-the-counter prevention